YaFarm Technologies Announces ISCI IRB Submission
15 Février 2013 - 1:30PM
Marketwired
YaFarm Technologies, Inc. (PINKSHEETS: YFRM) (YaFarm, or the
Company) is pleased to announce that The Integrative Stem Cell
Institute (ISCI), a premier provider of point-of-care, stem
cell-based therapies, has submitted its complete protocols for the
treatment of chronic and degenerative diseases to the Institutional
Review Board (IRB) of the International Cell Surgical Society
(ICSS).
ISCI submitted the protocols for independent evaluation and
review of its safety study in the use of adipose derived progenitor
(stem) cells in the treatment of chronic and degenerative diseases.
The IRB will study ISCI's procedures for harvesting, processing,
and re-implanting the patient's own stem cells to confirm patients
are not put at risk. The IRB will also review the scientific and
medical qualifications of the investigators, the informed consent
and patient candidacy forms, and the rationale for the study.
The ICSS IRB is registered with the Office for Human Research
Protections, which is a part of the U.S. Department of Health and
Human Services. The IRB is comprised of both medical and scientific
experts, as well as informed community members, and is managed by
the International Cell Surgical Society, a California based
physician organization dedicated to education, advancing research,
and advocating for cell-based regenerative medicine.
The studies ISCI submitted for approval will be conducted within
its state-of-the art laboratory and the fully integrative medical
facility of the ISCI, housed in the Hospital Galenia in Cancun,
Mexico. As part of the submission, the ISCI will also provide the
IRB with the methodology for providing long-term follow up and the
conditions specific metrics and safety data that will be collected
for review. This model includes the use of the international
physician network, the ISCP, to provide independent collection of
patient outcomes.
"IRB submission and review is a critical element of our clinical
studies programs," says David Audley, CEO of the ISCI. "Many
clinics do not take this extra step, but we genuinely believe that
patient safety only comes through transparency and oversight. The
most effective way we will be able to advance this field, and to
deliver on the promise of regenerative medicine, is collect patient
data, report it, and publish it," Mr. Audley continued, "We are
excited about this important step and look forward to working with
the IRB."
About The Integrative Stem Cell Institute
(ISCI) The Integrative Stem Cell Institute (ISCI) is a premier
provider of point-of-care, stem cell-based therapies for patients
from around the world. With a state of the art laboratory housed
within the Hospital Galenia in Cancun, Mexico, the ISCI combines
the most advanced scientific application of stem cells with second
to none medical care within the structure of adaptive clinical
trials to effectively track long term outcomes and assure patient
safety. More information on the Integrative Stem Cell Institute is
available at www.iscelli.com
SAFE HARBOR STATEMENT
This press release may contain certain forward-looking
statements and information, as defined within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and is subject to the Safe Harbor
created by those sections. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. This material contains statements about
expected future events and/or financial results that are
forward-looking in nature and subject to risks and uncertainties.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition, adequate financing, and
other material risks. Such forward-looking statements by definition
involve risks, uncertainties and other factors, which may cause the
actual results, performance, or achievements to be materially
different from the statements made herein.
Contact: The Integrative Stem Cell Institute Contact: Miranda
Abrahams Miranda@iscelli.com Investor Contact Atlanta Capital
Partners, LLC David Kugelman (866) 692-6847 info@atlcp.com
Profile Solutions (CE) (USOTC:PSIQ)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Profile Solutions (CE) (USOTC:PSIQ)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024